Overview

Clinical Study of QL1706 Combined With Chemotherapy in the Treatment of Patients With Advanced Non-small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of QL1706 when given in combination with bevacizumab, paclitaxel or pemetrexed, and carboplatin in patients with Stage IIIB/C and Stage IV Non-Small Cell Lung Cancer (NSCLC). The study will be conducted in two phases: Induction Phase and Maintenance Phase.
Phase:
Phase 2
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.